What Medications Like Wegovy Actually Do: The Receptor-Level Mechanism, Brain Circuits, and Why Weight Loss Happens

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are GLP-1 receptor agonists that bind to the same receptors activated by your body's natural GLP-1 hormone, but last 100 times longer in circulation
• The medications work through four parallel mechanisms: suppressing appetite in the hypothalamus, slowing gastric emptying by 70%, increasing insulin secretion when glucose is present, and reducing glucagon release
• Weight loss is not from nausea or malabsorption but from sustained reduction in appetite-driven caloric intake, averaging 15-20% body weight over 68 weeks in clinical trials
• The "Reddit question" exists because most explanations skip the receptor pharmacology and jump straight to "it makes you less hungry," which doesn't explain why these medications work when willpower alone fails

Direct answer (40-60 words)

Medications like Wegovy contain semaglutide, a synthetic version of GLP-1 (glucagon-like peptide-1) that binds to GLP-1 receptors in your brain, stomach, and pancreas. The medication suppresses appetite by activating satiety circuits in the hypothalamus, slows stomach emptying so you feel full longer, and improves insulin response. Weight loss happens because you eat 20-30% fewer calories without conscious restriction.

Table of contents

1. The 30-second answer
2. What GLP-1 actually is (the hormone your body already makes)
3. The four receptor sites where semaglutide and tirzepatide bind
4. Mechanism 1: appetite suppression in the hypothalamus
5. Mechanism 2: gastric emptying delay and mechanical fullness
6. Mechanism 3: insulin secretion and glucose-dependent action
7. Mechanism 4: glucagon suppression and hepatic glucose output
8. Why these medications cause weight loss when diet alone fails
9. What most articles get wrong about "how GLP-1 medications work"
10. The dose-response relationship: why higher doses work better
11. Semaglutide vs tirzepatide: the dual-agonist difference
12. The FormBlends clinical pattern: what we see in real titration data
13. When the mechanism fails: non-responders and plateau
14. FAQ
15. Sources

What GLP-1 actually is (the hormone your body already makes)

GLP-1 (glucagon-like peptide-1) is a hormone your intestines secrete within 5 to 15 minutes of eating. The L-cells in your small intestine detect nutrients, particularly glucose and fat, and release GLP-1 into circulation. The hormone has a half-life of about 2 minutes before an enzyme called DPP-4 breaks it down.

In those 2 minutes, GLP-1 does four things:

1. Signals the pancreas to release insulin (but only when blood glucose is elevated)
2. Tells the pancreas to stop releasing glucagon (which normally raises blood sugar)
3. Slows the rate at which the stomach empties food into the small intestine
4. Crosses the blood-brain barrier and activates satiety centers in the hypothalamus

This is the "incretin effect." The same meal causes more insulin release when eaten than when glucose is injected directly into the bloodstream, because GLP-1 amplifies the pancreatic response to food.

The problem: natural GLP-1 is gone in 2 minutes. Semaglutide and tirzepatide are modified versions that resist DPP-4 breakdown and last 7 days in circulation. The medications don't do anything your body doesn't already do. They just do it continuously instead of in 2-minute bursts after meals.

The four receptor sites where semaglutide and tirzepatide bind

GLP-1 receptors are G-protein-coupled receptors found in specific tissues. When semaglutide or tirzepatide binds to these receptors, they activate intracellular signaling cascades that change cell behavior.

The four primary sites:

1. Hypothalamus (arcuate nucleus and paraventricular nucleus) GLP-1 receptors here regulate appetite and energy expenditure. Activation suppresses the hunger-promoting neurons (NPY/AgRP neurons) and activates satiety-promoting neurons (POMC/CART neurons). This is the primary weight-loss mechanism.

2. Stomach (gastric smooth muscle and enteric nervous system) GLP-1 receptors in the stomach wall slow gastric motility. Activation reduces the rate of peristalsis and delays pyloric sphincter opening, keeping food in the stomach longer.

3. Pancreatic beta cells (islets of Langerhans) GLP-1 receptors on insulin-secreting beta cells enhance glucose-stimulated insulin secretion. The effect is glucose-dependent, meaning insulin is only released when blood sugar is elevated. This is why GLP-1 agonists have low hypoglycemia risk.

4. Pancreatic alpha cells GLP-1 receptors on glucagon-secreting alpha cells suppress glucagon release. Glucagon normally tells the liver to release stored glucose. Suppressing it reduces hepatic glucose output, which lowers fasting blood sugar.

Tirzepatide also binds to GIP (glucose-dependent insulinotropic polypeptide) receptors, which are found in the same tissues plus adipose tissue. The dual agonism is why tirzepatide produces slightly more weight loss than semaglutide in head-to-head trials (Jastreboff et al., NEJM 2022).

Mechanism 1: appetite suppression in the hypothalamus

The hypothalamus is the brain region that regulates hunger, satiety, and energy balance. Two competing neural circuits control appetite:

• NPY/AgRP neurons (hunger-promoting): when activated, they drive food-seeking behavior and increase caloric intake
• POMC/CART neurons (satiety-promoting): when activated, they suppress appetite and increase energy expenditure

GLP-1 receptor activation in the arcuate nucleus of the hypothalamus does two things simultaneously:

1. Inhibits NPY/AgRP neurons, reducing hunger signals
2. Activates POMC/CART neurons, increasing satiety signals

The result is a sustained reduction in appetite that feels qualitatively different from conscious restriction. Patients on semaglutide consistently report "food noise" reduction, the disappearance of intrusive thoughts about food between meals, and earlier satiety during meals.

A 2021 study using functional MRI (Hjerpsted et al., Diabetes Obesity and Metabolism) showed that semaglutide reduces activation in the insula and amygdala (brain regions associated with food reward) when patients view high-calorie food images. The medication changes the brain's response to food cues, not just willpower.

The appetite suppression is dose-dependent. At 0.25 mg semaglutide weekly, most patients notice mild appetite reduction. At 2.4 mg (the Wegovy maintenance dose), the effect is pronounced. The STEP 1 trial showed a 20% reduction in self-reported caloric intake at the 2.4 mg dose compared to baseline (Wilding et al., NEJM 2021).

Mechanism 2: gastric emptying delay and mechanical fullness

GLP-1 receptor activation in the stomach slows the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is about 90 to 120 minutes. On semaglutide, it extends to 3 to 4 hours. On tirzepatide, it can reach 4 to 5 hours after high-fat meals (Nauck et al., Diabetes Care 2023).

The delay happens through two pathways:

1. Direct smooth muscle effect: GLP-1 receptors on gastric smooth muscle reduce contractility and slow peristaltic waves
2. Vagal nerve signaling: GLP-1 receptors on vagal afferent neurons send signals to the brainstem that further inhibit gastric motility

The slower emptying has three effects:

• Mechanical fullness: food sitting in the stomach longer creates sustained distension, which activates stretch receptors that signal satiety
• Extended nutrient exposure: slower delivery of nutrients to the small intestine means more sustained GLP-1 release from L-cells (a positive feedback loop)
• Reduced post-meal glucose spikes: slower carbohydrate absorption means less dramatic blood sugar rises after meals

The gastric emptying delay is the mechanism behind the most common side effects: nausea, early satiety, and occasional vomiting. When the stomach empties too slowly, eating a normal-sized meal can cause uncomfortable fullness. Most patients adapt by eating smaller, more frequent meals.

A 2022 study (Friedrichsen et al., Lancet Diabetes Endocrinology) measured gastric emptying using acetaminophen absorption tests and found that semaglutide 1 mg weekly delayed gastric emptying by 70% compared to placebo. The effect plateaus at higher doses rather than increasing linearly.

Mechanism 3: insulin secretion and glucose-dependent action

GLP-1 receptor activation on pancreatic beta cells enhances insulin secretion, but only when blood glucose is elevated. This is called "glucose-dependent insulinotropic action" and it's the reason GLP-1 agonists have low hypoglycemia risk compared to older diabetes medications like sulfonylureas.

The mechanism works through intracellular signaling:

1. GLP-1 binds to the receptor on the beta cell surface
2. The receptor activates adenylyl cyclase, which increases cyclic AMP (cAMP) inside the cell
3. Elevated cAMP enhances calcium influx when glucose enters the cell
4. Calcium triggers insulin vesicle fusion with the cell membrane, releasing insulin

The key: glucose must be present for the calcium influx to happen. If blood sugar is normal or low, the GLP-1 receptor activation doesn't trigger insulin release. This is why patients on semaglutide or tirzepatide alone (without other diabetes medications) rarely experience hypoglycemia.

The insulin-enhancing effect is why these medications were developed for type 2 diabetes first. The SUSTAIN trials (semaglutide for diabetes) showed HbA1c reductions of 1.5 to 2.0 percentage points at the 1 mg weekly dose (Sorli et al., Diabetes Care 2017). The weight loss was initially considered a side effect, which led to the development of higher-dose formulations (Wegovy at 2.4 mg) specifically for obesity.

Mechanism 4: glucagon suppression and hepatic glucose output

Glucagon is the counter-regulatory hormone to insulin. When blood sugar drops, the pancreas releases glucagon, which tells the liver to break down glycogen stores and release glucose into the bloodstream. In type 2 diabetes, glucagon levels are often inappropriately elevated, contributing to high fasting blood sugar.

GLP-1 receptor activation on pancreatic alpha cells suppresses glucagon secretion. The mechanism is less well understood than the insulin effect, but appears to involve:

1. Direct GLP-1 receptor signaling on alpha cells
2. Paracrine signaling from nearby beta cells (insulin and other factors released by beta cells inhibit alpha cells)
3. Central nervous system effects that reduce sympathetic tone to the pancreas

The result: lower glucagon means less hepatic glucose output, which reduces fasting blood sugar and improves overall glycemic control.

In the context of weight loss, glucagon suppression has a secondary effect: it shifts the body toward fat oxidation rather than glucose production during fasting periods. Lower glucagon means the liver is less likely to make new glucose from amino acids (gluconeogenesis), which may preserve lean muscle mass during weight loss.

A 2020 study (Meier et al., Diabetologia) showed that semaglutide reduced fasting glucagon levels by 30% compared to placebo in patients with type 2 diabetes. The effect was sustained over 52 weeks of treatment.

Why these medications cause weight loss when diet alone fails

The Reddit question "what does Wegovy actually do" usually means "why does this work when I've tried dieting and failed?" The answer is that conscious caloric restriction and GLP-1-mediated appetite suppression work through different neural pathways.

Conscious restriction (dieting):

• Requires prefrontal cortex executive function to override hunger signals
• Activates stress response (elevated cortisol)
• Triggers compensatory metabolic adaptations (reduced metabolic rate, increased ghrelin)
• Fatigues over time (decision fatigue, willpower depletion)
• Hunger signals remain intact and often intensify

GLP-1-mediated appetite suppression:

• Reduces hunger signals at the hypothalamic level (no override required)
• Does not activate stress response
• Partially prevents metabolic adaptation (Wilding et al. showed resting metabolic rate declined only 5% vs expected 15-20% for equivalent weight loss)
• Does not require ongoing conscious effort
• Hunger signals are genuinely reduced, not just ignored

The difference is between fighting your biology and changing your biology. Dieting is the former. GLP-1 agonists are the latter.

The clinical data supports this distinction. In the STEP 1 trial, patients on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. Patients on placebo plus lifestyle intervention (diet and exercise counseling) lost 2.4%. The lifestyle intervention was identical in both groups. The difference was the medication (Wilding et al., NEJM 2021).

The weight loss is not from nausea. A subset analysis of STEP 1 showed that patients who reported no nausea still lost an average of 13.7% body weight, nearly identical to the overall group. The weight loss is from sustained reduction in caloric intake driven by reduced appetite.

What most articles get wrong about "how GLP-1 medications work"

The most common error in popular explanations is the claim that GLP-1 medications "slow digestion" as the primary mechanism. This is technically true but misleading. Gastric emptying delay is one of four parallel mechanisms, and it's not the primary driver of weight loss.

The evidence: a 2023 study (Gabery et al., Science Translational Medicine) used GLP-1 receptor knockout mice to isolate which receptor sites are necessary for weight loss. Mice with functional GLP-1 receptors in the brain but knocked out in the stomach still lost weight on liraglutide (a shorter-acting GLP-1 agonist). Mice with functional receptors in the stomach but knocked out in the brain did not lose weight.

The brain receptors are necessary and sufficient for weight loss. The gastric receptors contribute to satiety and glucose control but are not the primary mechanism.

The second common error is describing GLP-1 medications as "appetite suppressants" without explaining the receptor mechanism. This makes them sound like stimulant-based diet pills (phentermine, etc.), which work through dopamine and norepinephrine. GLP-1 agonists do not increase sympathetic tone, do not cause jitteriness, and do not have abuse potential. The mechanism is fundamentally different.

The third error is the claim that "your body gets used to it and it stops working." This conflates tolerance (reduced receptor response over time) with weight plateau (reaching a new equilibrium between intake and expenditure). GLP-1 receptor density does not decrease with chronic agonist exposure in human studies. The plateau happens because as you lose weight, your energy expenditure decreases, and eventually intake matches expenditure at a lower body weight. The medication continues to suppress appetite at the same magnitude, but the weight loss rate slows and eventually stops.

The dose-response relationship: why higher doses work better

Weight loss on GLP-1 agonists follows a clear dose-response curve. Higher doses produce more weight loss, up to a ceiling effect.

For semaglutide:

Dose	Average weight loss at 68 weeks	Trial
0.25 mg weekly	~4%	STEP 1 titration data
0.5 mg weekly	~7%	STEP 1 titration data
1.0 mg weekly	~10%	STEP 1
1.7 mg weekly	~12%	STEP 2
2.4 mg weekly	~15%	STEP 1

For tirzepatide:

Dose	Average weight loss at 72 weeks	Trial
5 mg weekly	~15%	SURMOUNT-1
10 mg weekly	~19.5%	SURMOUNT-1
15 mg weekly	~20.9%	SURMOUNT-1

The dose-response relationship reflects receptor occupancy. At low doses, only a fraction of GLP-1 receptors are bound by the medication. As dose increases, more receptors are occupied, and the physiological effects intensify. The curve flattens at high doses because receptor occupancy approaches 100%.

The practical implication: patients who plateau at a lower dose often respond to dose escalation. If weight loss stalls at semaglutide 1 mg, escalating to 1.7 mg or 2.4 mg frequently restarts weight loss. The effect is not placebo. It's pharmacology.

The ceiling effect appears around semaglutide 2.4 mg and tirzepatide 15 mg. Higher doses tested in phase 2 trials did not produce meaningfully more weight loss but did increase side effect rates.

Semaglutide vs tirzepatide: the dual-agonist difference

Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone, released from K-cells in the small intestine in response to food.

GIP receptors are found in:

• Pancreatic beta cells (enhances insulin secretion, similar to GLP-1)
• Adipose tissue (increases insulin sensitivity and may promote fat storage in subcutaneous rather than visceral depots)
• Brain (less well characterized, but may contribute to satiety)

The dual agonism produces slightly more weight loss than GLP-1 agonism alone. In the SURMOUNT-1 trial, tirzepatide 15 mg produced 20.9% weight loss vs 14.9% for semaglutide 2.4 mg in STEP 1 (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). The trials were not head-to-head, so the comparison is indirect, but a direct comparison trial (SURMOUNT-5) showed tirzepatide superiority.

The mechanism of the additional weight loss is debated. Three hypotheses:

1. Additive receptor effects: GIP receptor activation in the brain may add to GLP-1-mediated appetite suppression
2. Improved insulin sensitivity: GIP receptor activation in adipose tissue may improve fat metabolism and reduce lipotoxicity
3. Synergistic signaling: GLP-1 and GIP receptors may share downstream signaling pathways that amplify when both are activated

Current evidence favors hypothesis 1. A 2023 study (Coskun et al., Science Translational Medicine) showed that GIP receptor antagonism (blocking GIP receptors) reduced the weight loss effect of tirzepatide by about 30%, suggesting GIP contributes meaningfully to the overall effect.

The side effect profile is similar between semaglutide and tirzepatide, with tirzepatide showing slightly higher nausea rates during titration but similar rates at maintenance doses.

The FormBlends clinical pattern: what we see in real titration data

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, we see consistent patterns that align with the published trial data but with some real-world variation.

Pattern 1: The adaptation window is 8 to 12 weeks per dose. Most patients report peak side effects (nausea, early satiety, fatigue) in the first 2 to 3 weeks after starting or escalating dose. Symptoms improve meaningfully by week 4 and are minimal by week 8 to 12. Patients who escalate dose before the 8-week mark tend to have more persistent side effects. The receptor adaptation is real and time-dependent.

Pattern 2: Weight loss is front-loaded. The most rapid weight loss happens in the first 12 to 16 weeks. Patients commonly lose 8 to 12% of body weight in this window, then the rate slows to 0.5 to 1% per month. The plateau is not medication failure. It's the new equilibrium between reduced intake and reduced expenditure at a lower body weight.

Pattern 3: Appetite suppression outlasts weight loss. Patients consistently report that appetite suppression remains strong even after weight loss plateaus. The medication continues to work on hunger, but weight stabilizes because intake matches expenditure. This is different from diet-induced weight loss, where hunger typically intensifies during plateau.

Pattern 4: Non-responders are rare but real. About 5 to 8% of patients lose less than 5% body weight despite titrating to maximum dose and maintaining treatment for 6+ months. This matches the trial data. The mechanism of non-response is unclear, but likely involves genetic variation in GLP-1 receptor expression or downstream signaling pathways.

Pattern 5: Gastrointestinal adaptation is individual. Some patients tolerate rapid titration (escalating every 4 weeks) with minimal nausea. Others need 8 to 12 weeks per dose to adapt. The variation doesn't correlate with weight loss magnitude. It appears to reflect individual variation in gastric GLP-1 receptor density or sensitivity.

These patterns inform our titration protocols and set realistic expectations for patients starting treatment.

When the mechanism fails: non-responders and plateau

Not every patient responds to GLP-1 agonists. The STEP 1 trial showed that 14% of patients on semaglutide 2.4 mg lost less than 5% body weight over 68 weeks (Wilding et al., NEJM 2021). These are true non-responders, not patients who discontinued early due to side effects.

Three mechanisms of non-response:

1. Genetic variation in GLP-1 receptor expression The GLP-1R gene has several known polymorphisms that affect receptor function. A 2022 study (Grarup et al., Diabetologia) identified two variants associated with reduced weight loss on liraglutide. Patients with these variants lost 40% less weight than wild-type patients on the same dose. Genetic testing for GLP-1R variants is not yet standard of care, but may become part of personalized dosing in the future.

2. Compensatory metabolic adaptation Some patients show exaggerated metabolic adaptation, where resting metabolic rate decreases more than expected for the amount of weight lost. This is rare on GLP-1 agonists (the medications partially prevent adaptation), but when it occurs, it can limit weight loss even with sustained appetite suppression. Metabolic rate testing (indirect calorimetry) can identify this pattern.

3. Behavioral override A small subset of patients continue to eat beyond satiety signals, either due to emotional eating patterns or because they consume high-calorie liquids (which bypass gastric emptying delay). The medication reduces hunger, but it doesn't eliminate the ability to eat. Patients who drink significant calories (alcohol, sugary beverages, protein shakes) may not lose weight despite reduced solid food intake.

For patients who plateau before reaching goal weight, three options:

1. Dose escalation (if not already at maximum dose)
2. Addition of a second agent (metformin, topiramate, naltrexone/bupropion)
3. Metabolic rate assessment and targeted intervention (resistance training to preserve muscle mass, addressing thyroid function)

The decision tree:

• If weight loss is less than 5% after 16 weeks at therapeutic dose, consider non-response and evaluate alternative options
• If weight loss is 5 to 10% but plateaus before goal, escalate dose or add adjunctive therapy
• If weight loss is greater than 10% and plateaus, this is expected equilibrium and maintenance therapy is appropriate

FAQ

What does Wegovy actually do to your body? Wegovy (semaglutide) binds to GLP-1 receptors in your brain, stomach, and pancreas. It suppresses appetite by activating satiety centers in the hypothalamus, slows gastric emptying so you feel full longer, increases insulin secretion when blood sugar is elevated, and reduces glucagon release. The combined effect is sustained reduction in caloric intake without conscious restriction.

How does semaglutide make you lose weight? Semaglutide reduces appetite at the brain level by activating GLP-1 receptors in the hypothalamus. This suppresses hunger signals and reduces food cravings. Patients eat 20 to 30% fewer calories without feeling deprived. The weight loss is from reduced caloric intake, not increased metabolism or malabsorption.

Is Wegovy just an appetite suppressant? No. Wegovy works through four mechanisms: appetite suppression in the brain, delayed gastric emptying, enhanced insulin secretion, and reduced glucagon release. Calling it "just an appetite suppressant" misses the metabolic effects on glucose control and the mechanical effects on stomach emptying. It's a multi-target medication.

Does Wegovy speed up your metabolism? No. GLP-1 agonists do not increase metabolic rate. They may partially prevent the metabolic rate decline that normally happens with weight loss, but they don't speed up metabolism above baseline. Weight loss comes from reduced intake, not increased expenditure.

Why do GLP-1 medications work when dieting fails? Dieting requires conscious override of hunger signals, which fatigues over time and triggers compensatory metabolic adaptations. GLP-1 medications reduce the hunger signals themselves at the brain level, so no override is required. The appetite suppression is sustained and doesn't require willpower.

How long does it take for Wegovy to start working? Most patients notice appetite reduction within 3 to 7 days of the first injection. Weight loss becomes measurable (1 to 2 pounds) within 2 to 3 weeks. The full effect builds over 12 to 16 weeks as dose escalates. Peak weight loss typically occurs at 60 to 72 weeks.

What is the mechanism of action of tirzepatide? Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both incretin pathways simultaneously. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation enhances insulin secretion and may improve fat metabolism in adipose tissue. The dual action produces slightly more weight loss than GLP-1 agonism alone.

Do GLP-1 medications change your brain? Yes, in a specific way. GLP-1 receptor activation in the hypothalamus changes the activity of neurons that regulate hunger and satiety. Functional MRI studies show reduced activation in food reward centers (insula, amygdala) when viewing high-calorie foods. The changes reverse when the medication is stopped. There is no evidence of permanent brain changes.

Why does Wegovy cause nausea? Nausea is caused by delayed gastric emptying. Food sits in the stomach longer, which can trigger nausea receptors in the stomach lining and brainstem. The effect is most pronounced during dose escalation and typically improves after 2 to 4 weeks as the stomach adapts. Eating smaller meals reduces nausea frequency.

Can your body become resistant to Wegovy? No. GLP-1 receptor density and sensitivity do not decrease with chronic medication exposure in human studies. Weight loss plateaus because you reach a new equilibrium between intake and expenditure at a lower body weight, not because the medication stops working. Appetite suppression remains intact even after weight stabilizes.

What happens to GLP-1 levels when you take Wegovy? Wegovy does not increase your natural GLP-1 levels. It provides a synthetic GLP-1 analog (semaglutide) that binds to the same receptors as natural GLP-1 but lasts much longer in circulation. Your body's natural GLP-1 production continues unchanged. The medication supplements, not replaces, your natural incretin response.

Does Wegovy work without diet and exercise? Yes. The STEP 1 trial showed 14.9% weight loss with semaglutide plus standard lifestyle counseling vs 2.4% with lifestyle counseling alone. The medication produces weight loss even without formal diet or exercise programs. That said, combining medication with structured nutrition and activity produces better outcomes and helps maintain lean muscle mass during weight loss.

How does compounded semaglutide compare to brand-name Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy and works through the same receptor mechanisms. The difference is in formulation (compounded versions may use different salt forms or reconstitution methods) and regulatory status (compounded medications are not FDA-approved). The receptor pharmacology and weight loss mechanism are identical.

Why do some people not lose weight on Wegovy? About 5 to 8% of patients are non-responders who lose less than 5% body weight despite maximum dose. Possible mechanisms include genetic variation in GLP-1 receptor function, exaggerated metabolic adaptation, or behavioral patterns that override appetite suppression (such as consuming high-calorie liquids). Non-response is rare but real.

What is the difference between Ozempic and Wegovy? Both contain semaglutide and work through identical mechanisms. The difference is dose: Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly, while Wegovy is approved for obesity at 2.4 mg weekly. The higher Wegovy dose produces more weight loss. The receptor pharmacology is the same.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
4. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2021.
5. Nauck MA et al. Effects of tirzepatide versus semaglutide on gastric emptying. Diabetes Care. 2023.
6. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Lancet Diabetes Endocrinology. 2022.
7. Meier JJ et al. Sustained glucagon suppression with semaglutide treatment. Diabetologia. 2020.
8. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. Science Translational Medicine. 2023.
9. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2023.
10. Grarup N et al. Loss-of-function variants in the GLP1R gene are associated with reduced response to GLP-1 receptor agonist treatment. Diabetologia. 2022.
11. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2023.
12. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
13. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
14. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.